Aktie A14MJ5 PARNELL PHARMACEUTICALS HOLDINGS LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Parnell Pharmaceuticals Holdings Ltd

Aktien

A14MJ5

AU0000XINEU9

PARNF

Verzögert OTC Markets
Andere Börsenplätze
 17:07:19 22.12.2023 		% 5 Tage % 1. Jan.
0,000001 USD -99,00 % Intraday Chart für Parnell Pharmaceuticals Holdings Ltd -.--% -.--%
2022 Parnell Pharmaceuticals Holdings Ltd berichtet über die Ergebnisse für das Geschäftsjahr zum 31. Dezember 2021 CI
2019 Parnell Pharmaceuticals Holdings Ltd gibt die Finanzergebnisse für das am 31. Dezember 2018 abgeschlossene Geschäftsjahr bekannt und gibt eine Gewinnprognose für das Jahr 2019 ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Parnell Pharmaceuticals : Welcomes Dr. Chelsie Estey as Vice President of U.S. Pet Care
Parnell Pharmaceuticals : Adds Three Experts to Leadership Team
Parnell Pharmaceuticals : Two New Territory Business Managers Help Parnell Better Serve Producers and Veterinarians
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum
Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners made an offer to acquire Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $7.2 million.
Parnell Pharmaceuticals Announces Nomovid Antiviral Nasal Spray
Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2019
Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Full Year Ended 31 December 2018; Provides Earnings Guidance for the Year 2019
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018; Revises Revenue Guidance for the Year 2018
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Revised Earnings Guidance for the Full Year 2018
Parnell Pharmaceuticals Holdings Ltd Reports Audited Earnings Results for the First Quarter Ended March 31, 2018; Revises Earnings Guidance for the Year 2018
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017
Certain Ordinary Shares of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
Certain Options of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
Certain Warrants of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.
Parnell Pharmaceuticals Holdings Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14MJ5 Aktie
  4. Nachrichten Parnell Pharmaceuticals Holdings Ltd
  5. Andere Sprachen